A new partnership has led to the development of the first-ever automated insulin delivery (AID) system that incorporates a one-year glucose sensor.
Sequel Med Tech, LLC and Senseonics have teamed up to feature the 1-year implantable Eversense 365 continuous glucose monitor (CGM) as a component of the Twiist AID. In May 2024, the FDA deemed the Eversense to be compatible for use with insulin pumps.
The Eversense sensor is implanted subcutaneously into the upper arm by a healthcare professional, with the one-year rechargeable transmitter worn above it. The Twiist insulin pump is reusable for up to three years, with a 300-unit reservoir that is replaced every three days with infusion set changes.
The Twiist AID system is the first to directly measure the volume of microdosed insulin and automatically adjusts basal insulin delivery based on real-time readings from the sensor and predicted glucose levels.
The Twiist system is set to be available in select areas of the United States during the second quarter of 2025. While the Twiist AID is approved for people aged six years or older with Type 1 diabetes, the Eversense indication is for those aged 18 years or older, so that age restriction will apply to the system as a whole.
To find out more, CLICK HERE.
